FSI 10-Q Quarterly Report March 31, 2024 | Alphaminr
FLEXIBLE SOLUTIONS INTERNATIONAL INC

FSI 10-Q Quarter ended March 31, 2024

FLEXIBLE SOLUTIONS INTERNATIONAL INC
10-Ks and 10-Qs
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
10-Q
10-Q
10-Q
10-K
PROXIES
DEF 14A
DEF 14A
DEF 14A
DEF 14A
DEF 14A
DEF 14A
DEF 14A
DEF 14A
DEF 14A
DEF 14A
DEF 14A
DEF 14A
DEF 14A
DEF 14A
DEF 14A
false Q1 --12-31 0001069394 A0 0001069394 2024-01-01 2024-03-31 0001069394 2024-05-15 0001069394 2024-03-31 0001069394 2023-12-31 0001069394 2023-01-01 2023-03-31 0001069394 2022-12-31 0001069394 2023-03-31 0001069394 us-gaap:CommonStockMember 2023-12-31 0001069394 FSI:CapitalInExcessOfParValueMember 2023-12-31 0001069394 us-gaap:RetainedEarningsMember 2023-12-31 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001069394 us-gaap:ParentMember 2023-12-31 0001069394 us-gaap:NoncontrollingInterestMember 2023-12-31 0001069394 us-gaap:CommonStockMember 2022-12-31 0001069394 FSI:CapitalInExcessOfParValueMember 2022-12-31 0001069394 us-gaap:RetainedEarningsMember 2022-12-31 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001069394 us-gaap:ParentMember 2022-12-31 0001069394 us-gaap:NoncontrollingInterestMember 2022-12-31 0001069394 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001069394 FSI:CapitalInExcessOfParValueMember 2024-01-01 2024-03-31 0001069394 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001069394 us-gaap:ParentMember 2024-01-01 2024-03-31 0001069394 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001069394 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001069394 FSI:CapitalInExcessOfParValueMember 2023-01-01 2023-03-31 0001069394 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001069394 us-gaap:ParentMember 2023-01-01 2023-03-31 0001069394 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001069394 us-gaap:CommonStockMember 2024-03-31 0001069394 FSI:CapitalInExcessOfParValueMember 2024-03-31 0001069394 us-gaap:RetainedEarningsMember 2024-03-31 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001069394 us-gaap:ParentMember 2024-03-31 0001069394 us-gaap:NoncontrollingInterestMember 2024-03-31 0001069394 us-gaap:CommonStockMember 2023-03-31 0001069394 FSI:CapitalInExcessOfParValueMember 2023-03-31 0001069394 us-gaap:RetainedEarningsMember 2023-03-31 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001069394 us-gaap:ParentMember 2023-03-31 0001069394 us-gaap:NoncontrollingInterestMember 2023-03-31 0001069394 FSI:MendotaLLCMember 2024-01-01 2024-03-31 0001069394 FSI:ENPInvestmentsLLCAndENPMendotaMember 2024-01-01 2024-03-31 0001069394 FSI:ENPPeruMember FSI:UnrelatedPartyMember 2022-01-01 2022-12-31 0001069394 FSI:ENPPeruMember 2022-01-01 2022-12-31 0001069394 FSI:ENPPeruMember 2023-01-01 2023-12-31 0001069394 FSI:MendotaLLCMember 2023-01-01 2023-12-31 0001069394 FSI:MendotaLLCMember FSI:UnrelatedPartyMember 2023-12-31 0001069394 FSI:FirstTermMember 2024-03-31 0001069394 FSI:SecondTermMember 2024-03-31 0001069394 FSI:ThirdTermMember 2024-03-31 0001069394 FSI:FourthTermMember 2024-03-31 0001069394 FSI:FifthTermMember 2024-03-31 0001069394 us-gaap:ShippingAndHandlingMember 2024-01-01 2024-03-31 0001069394 us-gaap:ShippingAndHandlingMember 2023-01-01 2023-03-31 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:RevenueFromContractWithCustomerMember 2024-01-01 2024-03-31 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-03-31 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:AccountsReceivableMember 2024-01-01 2024-03-31 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:AccountsReceivableMember 2023-01-01 2023-12-31 0001069394 FSI:InvestmentMember 2024-01-01 2024-03-31 0001069394 us-gaap:MachineryAndEquipmentMember 2024-01-01 2024-03-31 0001069394 us-gaap:OfficeEquipmentMember 2024-01-01 2024-03-31 0001069394 us-gaap:BuildingAndBuildingImprovementsMember 2024-01-01 2024-03-31 0001069394 us-gaap:AutomobilesMember 2024-01-01 2024-03-31 0001069394 us-gaap:TechnologyEquipmentMember 2024-01-01 2024-03-31 0001069394 us-gaap:LeaseholdImprovementsMember 2024-01-01 2024-03-31 0001069394 us-gaap:CustomerRelationshipsMember 2024-01-01 2024-03-31 0001069394 2023-01-01 2023-12-31 0001069394 us-gaap:BuildingAndBuildingImprovementsMember 2024-03-31 0001069394 us-gaap:AutomobilesMember 2024-03-31 0001069394 us-gaap:OfficeEquipmentMember 2024-03-31 0001069394 us-gaap:MachineryAndEquipmentMember 2024-03-31 0001069394 us-gaap:LandMember 2024-03-31 0001069394 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001069394 us-gaap:DevelopedTechnologyRightsMember 2024-03-31 0001069394 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0001069394 us-gaap:AutomobilesMember 2023-12-31 0001069394 us-gaap:OfficeEquipmentMember 2023-12-31 0001069394 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001069394 us-gaap:LandMember 2023-12-31 0001069394 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001069394 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001069394 FSI:EnPInvestmentsCorporationLLCMember 2022-12-31 0001069394 FSI:EnPInvestmentsCorporationLLCMember 2023-01-01 2023-12-31 0001069394 FSI:EnPInvestmentsCorporationLLCMember 2023-12-31 0001069394 FSI:EnPInvestmentsCorporationLLCMember 2024-01-01 2024-03-31 0001069394 FSI:EnPInvestmentsCorporationLLCMember 2024-03-31 0001069394 us-gaap:FiniteLivedIntangibleAssetsMember 2024-03-31 0001069394 FSI:EnpPeruInvestmentsLlcMember 2016-12-31 0001069394 FSI:NanoChemMember 2016-12-31 0001069394 FSI:ENPInvestmentsLLCMember 2016-12-31 0001069394 FSI:NanoChemMember 2022-06-30 0001069394 FSI:ENPPeruMember 2022-06-01 2022-06-30 0001069394 FSI:ENPPeruMember 2022-06-30 0001069394 FSI:EnpnvestmentsLlcMember 2023-12-31 0001069394 FSI:ENPInvestmentsLLCMember 2023-12-31 0001069394 FSI:ENPInvestmentsLLCMember 2023-06-30 0001069394 FSI:AppliedHoldingCorpMember 2018-12-31 0001069394 2021-01-01 2021-12-31 0001069394 2023-10-31 0001069394 FSI:TrioOpportunityCorpMember 2018-12-31 0001069394 FSI:TrioOpportunityCorpMember 2023-04-30 0001069394 us-gaap:CommonClassBMember FSI:TrioOpportunityCorpMember 2018-12-01 2018-12-31 0001069394 us-gaap:CommonClassBMember FSI:TrioOpportunityCorpMember 2018-12-31 0001069394 FSI:FloridaBasedLLCMember 2019-01-31 0001069394 FSI:FloridaBasedLLCMember 2024-01-01 2024-03-31 0001069394 FSI:FloridaBasedLLCMember 2023-01-01 2023-03-31 0001069394 FSI:FloridaBasedLLCMember 2024-03-31 0001069394 FSI:FloridaBasedLLCMember 2023-12-31 0001069394 FSI:LygosIncMember 2020-12-01 2020-12-31 0001069394 FSI:LygosIncMember 2021-01-01 2021-12-31 0001069394 FSI:LygosIncMember 2021-12-31 0001069394 FSI:EnpPeruInvestmentsLlcMember 2024-01-01 2024-03-31 0001069394 FSI:EnpPeruInvestmentsLlcMember 2022-12-31 0001069394 FSI:EnpPeruInvestmentsLlcMember 2023-01-01 2023-12-31 0001069394 FSI:EnpPeruInvestmentsLlcMember 2023-12-31 0001069394 FSI:EnpPeruInvestmentsLlcMember 2024-03-31 0001069394 FSI:FloridaBasedLLCMember 2022-12-31 0001069394 FSI:FloridaBasedLLCMember 2023-01-01 2023-12-31 0001069394 FSI:StockYardAndBankMember FSI:MidlandStatesBankMember FSI:NewAgreementMember 2023-06-30 0001069394 FSI:StockYardAndBankMember FSI:MidlandStatesBankMember FSI:NewAgreementMember 2023-06-01 2023-06-30 0001069394 FSI:StockYardAndBankMember FSI:MidlandStatesBankMember FSI:NewAgreementMember 2024-03-31 0001069394 FSI:StockYardAndBankMember FSI:MidlandStatesBankMember FSI:NewAgreementMember 2023-12-31 0001069394 FSI:NewAgreementMember FSI:NanoChemSolutionIncMember FSI:StockYardAndBankMember 2024-03-31 0001069394 us-gaap:NoncontrollingInterestMember FSI:StockYardAndBankMember 2024-03-31 0001069394 FSI:NewAgreementMember FSI:NanoChemSolutionIncMember FSI:StockYardAndBankMember 2023-12-31 0001069394 FSI:StockBankMember FSI:MidlandStatesBankMember FSI:NewAgreementMember 2023-06-30 0001069394 FSI:StockBankMember FSI:MidlandStatesBankMember FSI:NewAgreementMember 2023-06-01 2023-06-30 0001069394 FSI:StockBankMember FSI:MidlandStatesBankMember FSI:NewAgreementMember 2024-03-31 0001069394 FSI:StockBankMember FSI:MidlandStatesBankMember FSI:NewAgreementMember 2023-12-31 0001069394 FSI:NewAgreementMember FSI:NanoChemSolutionIncMember FSI:StockBankMember us-gaap:RevolvingCreditFacilityMember 2024-03-31 0001069394 FSI:NewAgreementMember FSI:NanoChemSolutionIncMember FSI:StockBankMember us-gaap:RevolvingCreditFacilityMember 2023-12-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPMendotaMember 2020-01-31 0001069394 FSI:StockYardsBankTrustMember FSI:EnpRealtyLLCMember 2020-01-01 2020-01-31 0001069394 FSI:StockYardsBankTrustMember FSI:EnpRealtyLLCMember 2020-01-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPMendotaMember 2020-01-01 2020-01-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPMendotaMember 2024-01-01 2024-03-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPMendotaMember 2023-01-01 2023-03-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPMendotaMember 2024-03-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPMendotaMember 2023-12-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:NanoChemMember 2022-06-30 0001069394 FSI:StockYardsBankTrustMember FSI:EnpRealtyLLCMember 2022-06-01 2022-06-30 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPPeruInvestmentsMember 2022-06-30 0001069394 FSI:NanoChemMember FSI:TermLoanMember FSI:MidlandBankMember 2024-01-01 2024-03-31 0001069394 FSI:NanoChemMember FSI:TermLoanMember FSI:MidlandBankMember 2023-01-01 2023-03-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:NanoChemMember 2024-03-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:NanoChemMember 2023-12-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPPeruOneMember 2020-01-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPPeruOneMember 2020-01-01 2020-01-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPPeruOneMember 2022-06-30 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPPeruOneMember 2024-01-01 2024-03-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPPeruOneMember 2023-01-01 2023-03-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPPeruOneMember 2024-03-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPPeruOneMember 2023-12-31 0001069394 FSI:TermLoanMember FSI:MidlandBankMember FSI:ENPPeruInvestmentsMember 2022-06-01 2022-06-30 0001069394 FSI:TermLoanMember FSI:MidlandBankMember us-gaap:PrimeRateMember FSI:ENPPeruInvestmentsMember 2022-06-30 0001069394 FSI:ENPPeruInvestmentsMember FSI:TermLoanMember FSI:MidlandBankMember 2024-01-01 2024-03-31 0001069394 FSI:ENPPeruInvestmentsMember FSI:TermLoanMember FSI:MidlandBankMember 2023-01-01 2023-03-31 0001069394 FSI:ENPPeruInvestmentsMember FSI:TermLoanMember FSI:MidlandBankMember 2024-03-31 0001069394 FSI:ENPPeruInvestmentsMember FSI:TermLoanMember FSI:MidlandBankMember 2023-12-31 0001069394 FSI:TermLoanMember FSI:NanoChemMember 2022-12-31 0001069394 FSI:TermLoanMember FSI:NanoChemMember 2024-01-01 2024-03-31 0001069394 FSI:TermLoanMember FSI:NanoChemMember 2023-01-01 2023-03-31 0001069394 FSI:TermLoanMember FSI:NanoChemMember 2024-03-31 0001069394 FSI:TermLoanMember FSI:NanoChemMember 2023-12-31 0001069394 FSI:TermLoanMember FSI:MendotaMember 2023-06-30 0001069394 FSI:MendotaMember FSI:TermLoanMember 2024-01-01 2024-03-31 0001069394 FSI:MendotaMember FSI:TermLoanMember 2023-01-01 2023-03-31 0001069394 FSI:TermLoanMember FSI:MendotaMember 2024-03-31 0001069394 FSI:TermLoanMember FSI:MendotaMember 2023-12-31 0001069394 FSI:StockYardsBankTrustMember 2024-03-31 0001069394 FSI:StockYardsBankTrustMember 2023-12-31 0001069394 FSI:StockYardsBankTrustOneMember 2024-03-31 0001069394 FSI:StockYardsBankTrustOneMember 2023-12-31 0001069394 FSI:StockYardsBankTrustTwoMember 2024-03-31 0001069394 FSI:StockYardsBankTrustTwoMember 2023-12-31 0001069394 FSI:StockYardsBankTrustThreeMember 2024-03-31 0001069394 FSI:StockYardsBankTrustThreeMember 2023-12-31 0001069394 FSI:StockYardsBankTrustFourMember 2024-03-31 0001069394 FSI:StockYardsBankTrustFourMember 2023-12-31 0001069394 FSI:StockYardsBankTrustFiveMember 2024-03-31 0001069394 FSI:StockYardsBankTrustFiveMember 2023-12-31 0001069394 FSI:ConsultantsMember 2024-01-01 2024-03-31 0001069394 FSI:ConsultantsMember 2023-01-01 2023-03-31 0001069394 FSI:EmployeesMember 2024-01-01 2024-03-31 0001069394 FSI:EmployeesMember 2023-01-01 2023-03-31 0001069394 us-gaap:CanadaRevenueAgencyMember 2024-03-31 0001069394 us-gaap:CanadaRevenueAgencyMember 2023-03-31 0001069394 us-gaap:CanadaRevenueAgencyMember 2024-01-01 2024-03-31 0001069394 us-gaap:CanadaRevenueAgencyMember 2023-01-01 2023-03-31 0001069394 srt:MinimumMember 2022-12-31 0001069394 srt:MaximumMember 2022-12-31 0001069394 srt:MinimumMember 2023-01-01 2023-12-31 0001069394 srt:MaximumMember 2023-01-01 2023-12-31 0001069394 srt:MinimumMember 2023-12-31 0001069394 srt:MaximumMember 2023-12-31 0001069394 srt:MinimumMember 2024-01-01 2024-03-31 0001069394 srt:MaximumMember 2024-01-01 2024-03-31 0001069394 srt:MinimumMember 2024-03-31 0001069394 srt:MaximumMember 2024-03-31 0001069394 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001069394 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001069394 FSI:ENPInvestmentsLLCMember 2024-01-01 2024-03-31 0001069394 FSI:ENPInvestmentsLLCMember 2024-03-31 0001069394 FSI:ENPInvestmentsLLCMember 2023-01-01 2023-03-31 0001069394 FSI:ENPInvestmentsLLCMember 2023-12-31 0001069394 FSI:MendotaLLCMember 2024-03-31 0001069394 FSI:ENPInvestmentsLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2022-12-31 0001069394 FSI:ENPInvestmentsLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2023-01-01 2023-12-31 0001069394 FSI:ENPInvestmentsLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2023-12-31 0001069394 FSI:ENPInvestmentsLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2024-01-01 2024-03-31 0001069394 FSI:ENPInvestmentsLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2024-03-31 0001069394 FSI:MendotaLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2022-12-31 0001069394 FSI:MendotaLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2023-01-01 2023-12-31 0001069394 FSI:MendotaLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2023-12-31 0001069394 FSI:MendotaLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2024-01-01 2024-03-31 0001069394 FSI:MendotaLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2024-03-31 0001069394 us-gaap:AccountsReceivableMember FSI:ThreeCustomersMember 2024-03-31 0001069394 FSI:ThreeCustomersMember us-gaap:AccountsReceivableMember 2024-01-01 2024-03-31 0001069394 us-gaap:AccountsReceivableMember FSI:ThreeCustomersMember 2023-03-31 0001069394 FSI:ThreeCustomersMember us-gaap:AccountsReceivableMember 2023-01-01 2023-03-31 0001069394 FSI:EWCPMember FSI:SegmentMember 2024-01-01 2024-03-31 0001069394 FSI:BCPAMember FSI:SegmentMember 2024-01-01 2024-03-31 0001069394 FSI:SegmentMember 2024-01-01 2024-03-31 0001069394 FSI:EWCPMember FSI:SegmentMember 2023-01-01 2023-03-31 0001069394 FSI:BCPAMember FSI:SegmentMember 2023-01-01 2023-03-31 0001069394 FSI:SegmentMember 2023-01-01 2023-03-31 0001069394 country:CA 2024-01-01 2024-03-31 0001069394 country:CA 2023-01-01 2023-03-31 0001069394 FSI:UnitedStatesandAbroadMember 2024-01-01 2024-03-31 0001069394 FSI:UnitedStatesandAbroadMember 2023-01-01 2023-03-31 0001069394 country:CA 2024-03-31 0001069394 country:CA 2023-12-31 0001069394 country:US 2024-03-31 0001069394 country:US 2023-12-31 0001069394 us-gaap:SubsequentEventMember 2024-04-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure FSI:Segments iso4217:CAD utr:sqft

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

OR

TRANSITION REPORT PURSUANT TO 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission File Number: 001-31540

FLEXIBLE SOLUTIONS INTERNATIONAL INC.

(Exact Name of registrant as Specified in Its Charter)

Alberta 71-1630889
(State or other jurisdiction of (Employer
incorporation or organization) Identification No.)

6001 54 Ave.
Taber , Alberta , Canada T1G 1X4
(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number: (403) 223-2995

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock FSI NYSE American

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): ☐ Yes No

Class of Stock No. Shares Outstanding Date
Common 12,450,532 May 15, 2024

FORM 10-Q

Index

PART I. FINANCIAL INFORMATION 3
Item 1. Financial Statements. 3
(a) Unaudited Condensed Interim Consolidated Balance Sheets at March 31, 2024 and December 31, 2023. 3
(b) Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three Months Ended March 31, 2024 and 2023. 4
(c) Unaudited Condensed Interim Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023. 5
(d) Unaudited Condensed Interim Consolidated Statements of Stockholders’ Equity for the Three a Months Ended March 31, 2024 and 2023. 6
(e) Notes to Unaudited Condensed Interim Consolidated Financial Statements for the Period Ended March 31, 2024. 7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation. 23
Item 4. Controls and Procedures. 25
PART II. OTHER INFORMATION 25
Item 5. Other Information. 25
Item 6. Exhibits. 25
SIGNATURES 26

1

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements” for the purposes of the federal and state securities laws, including, but not limited to: any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.

Forward-looking statements may include the words “may,” “could,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words. These forward-looking statements present our estimates and assumptions only as of the date of this report. Except for our ongoing obligation to disclose material information as required by the federal securities laws, we do not intend, and undertake no obligation, to update any forward-looking statement.

Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. The factors impacting these risks and uncertainties include but are not limited to:

Increased competitive pressures from existing competitors and new entrants;
Increases in interest rates or our cost of borrowing or a default under any material debt agreement;
Deterioration in general or regional economic conditions;
Adverse state or federal legislation or regulation that increases the costs of compliance, or adverse findings by a regulator with respect to existing operations;
Loss of customers or sales weakness;
Inability to achieve future sales levels or other operating results;
The unavailability of funds for capital expenditures;
Operational inefficiencies in distribution or other systems; and
New tariffs relating to raw materials imported from China.

For a detailed description of these and other factors that could cause actual results to differ materially from those expressed in any forward-looking statement, please see “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023.

2

PART I FINANCIAL INFORMATION

Item 1. Financial Statements.

FLEXIBLE SOLUTIONS INTERNATIONAL, INC.

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS

(U.S. Dollars)

March 31, 2024 December 31, 2023
(Unaudited)
Assets
Current
Cash $ 5,302,954 $ 5,017,583
Term deposits (Note 2) 3,023,757 2,690,241
Accounts receivable, net (Note 4) 12,992,543 9,843,056
Inventories (Note 5) 10,459,256 11,134,889
Prepaid expenses and deposits 741,495 1,540,923
Total current assets 32,520,005 30,226,692
Property, equipment and leaseholds, net (Note 6) 13,267,240 13,171,787
Right of use assets (Note 3) - 115,293
Intangible assets (Note 7) 2,240,000 2,280,000
Long term deposits (Note 8) 840,592 824,254
Investments (Note 9) 5,889,161 6,033,960
Goodwill (Note 7) 2,534,275 2,534,275
Deferred tax asset (Note 2) 284,794 284,794
Total Assets $ 57,576,067 $ 55,471,055
Liabilities
Current
Accounts payable $ 1,397,915 $ 1,984,592
Accrued liabilities 699,005 284,131
Deferred revenue 131,827 148,292
Income taxes payable 4,749,391 4,485,213
Short term line of credit (Note 10) 3,259,935 1,810,479
Current portion of lease liability (Note 3) - 59,520
Current portion of long term debt (Note 11) 1,665,440 1,281,632
Total current liabilities 11,903,513 10,053,859
Lease liability (Note 3) - 55,773
Deferred income tax liability (Note 2) 260,047 260,047
Long term debt (Note 11) 6,321,396 6,833,304
Total Liabilities 18,484,956 17,202,983
Stockholders’ Equity
Capital stock (Note 13)
Authorized: 50,000,000 common shares with a par value of $ 0.001 each; 1,000,000 preferred shares with a par value of $ 0.01 each
Issued and outstanding:
12,450,532 (December 31, 2023: 12,432,523 ) common shares 12,451 12,436
Capital in excess of par value 18,211,607 17,932,015
Other comprehensive loss ( 767,923 ) ( 795,146 )
Accumulated earnings 18,510,277 18,053,051
Total stockholders’ equity – controlling interest 35,966,412 35,202,356
Non-controlling interests (Note 14) 3,124,699 3,065,716
Total Stockholders’ Equity 39,091,111 38,268,072
Total Liabilities and Stockholders’ Equity $ 57,576,067 $ 55,471,055

— See Notes to Unaudited Condensed Interim Consolidated Financial Statements —

3

FLEXIBLE SOLUTIONS INTERNATIONAL, INC.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(U.S. Dollars — Unaudited)

2024 2023
Three Months Ended March 31,
2024 2023
Sales $ 9,224,872 $ 9,847,517
Cost of sales 6,404,505 6,762,525
Gross profit 2,820,367 3,084,992
Operating Expenses
Wages 651,158 671,692
Administrative salaries and benefits 417,859 393,014
Insurance 244,260 201,530
Interest expense 175,266 134,870
Office and miscellaneous 157,623 98,846
Research 126,654 21,502
Consulting 99,921 62,977
Utilities 73,676 7,487
Advertising and promotion 66,949 48,398
Travel 66,261 61,652
Professional fees 60,995 62,767
Investor relations and transfer agent fee 39,304 89,892
Lease expense 30,150 25,295
Telecommunications 13,532 12,578
Shipping 7,829 4,666
Currency exchange ( 1,635 ) 2,576
Commissions - 2,985
Total operating expenses 2,229,802 1,902,727
Operating income 590,565 1,182,265
Loss on lease termination ( 41,350 ) -
Gain on investment 182,975 69,995
Interest income 48,197 12,011
Income before income tax 780,387 1,264,271
Income taxes
Income tax expense ( 264,178 ) ( 299,777 )
Net income for the period including non-controlling interests 516,209 964,494
Less: Net income attributable to non-controlling interests ( 58,983 ) ( 80,125 )
Net income attributable to controlling interest $ 457,226 $ 884,369
Income per share (basic and diluted) $ 0.04 $ 0.07
Weighted average number of common shares (basic) 12,449,699 12,432,914
Weighted average number of common shares (diluted) 12,449,699 12,532,404
Other comprehensive income (loss):
Net income 516,209 964,494
Unrealized income (loss) on foreign currency translations 27,223 ( 167,239 )
Total comprehensive income $ 543,432 $ 797,255
Comprehensive income – non-controlling interest ( 58,983 ) ( 80,125 )
Comprehensive income attributable to Flexible Solutions International Inc. $ 484,449 $ 717,130

— See Notes to Unaudited Condensed Interim Consolidated Financial Statements —

4

FLEXIBLE SOLUTIONS INTERNATIONAL, INC.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(U.S. Dollars — Unaudited)

2024 2023
Three Months Ended March 31,
2024 2023
Operating activities
Net income for the period including non-controlling interests $ 516,209 $ 964,494
Adjustments to reconcile net income to net cash:
Stock based compensation 253,357 185,298
Depreciation and amortization 422,669 342,810
Lease right of use amortization 13,694 12,775
Lease right of use financing 1,186 1,745
Loss on terminating lease 41,350
Gain on investment ( 182,975 ) ( 69,995 )
Changes in non-cash working capital items:
(Increase) decrease in accounts receivable ( 3,149,487 ) ( 1,383,671 )
Decrease in inventory 675,633 39,607
Decrease (increase) in prepaid expenses 799,428 ( 21,497 )
(Decrease) increase in accounts payable and accrued liabilities ( 171,028 ) ( 179,149 )
Increase in income taxes payable 264,178 152,577
Decrease in deferred revenue ( 16,465 ) ( 273,223 )
Cash used in operating activities ( 532,251 ) ( 228,229 )
Investing activities
Long term deposits ( 21,778 ) ( 342,747 )
Net purchase of property, equipment and leaseholds ( 478,123 ) ( 213,060 )
Proceeds of equity investment 327,000 -
Cash used in investing activities ( 172,901 ) ( 555,807 )
Financing activities
Draw from short term line of credit 1,449,456 844,913
Repayment of long term debt ( 185,916 ) ( 177,639 )
Proceeds of long term debt 57,816 -
Lease payments ( 50,790 ) ( 14,520 )
Proceeds from issuance of common stock 26,250 13,600
Cash used in financing activities 1,296,816 666,354
Effect of exchange rate changes on cash 27,223 ( 167,239 )
Inflow (outflow) of cash 618,887 ( 284,921 )
Cash, beginning 7,707,824 6,815,099
Cash, ending $ 8,326,711 $ 6,530,178
Cash consists of:
Cash $ 5,302,954 $ 5,530,178
Term Deposits 3,023,757 1,000,000
Cash resources $ 8,326,711 $ 6,530,178

— See Notes to Unaudited Condensed Interim Consolidated Financial Statements —

5

FLEXIBLE SOLUTIONS INTERNATIONAL, INC.

CONDENSED INTERIM Consolidated Statements of Stockholders’ Equity

(U.S. Dollars – Unaudited)

Shares

Par

Value

Capital in

Excess of

Par Value

Accumulated

Earnings

Other

Comprehensive

Income
(Loss)

Total

Non-

Controlling Interests

Total

Stockholders’

Equity

Balance December 31, 2023 12,435,532 $ 12,436 $ 17,932,015 $ 18,053,051 $ ( 795,146 ) $ 35,202,356 $ 3,065,716 $ 38,268,072
Translation adjustment 27,223 27,223 27,223
Net income 457,226 457,226 58,983 516,209
Common stock issued 15,000 15 26,235 26,250 26,250
Stock-based compensation 253,357 253,357 253,357
Balance March 31, 2024 12,450,532 $ 12,451 $ 18,211,607 $ 18,510,277 $ ( 767,923 ) $ 35,966,412 $ 3,124,699 $ 39,091,111

— See Notes to Unaudited Condensed Interim Consolidated Financial Statements —

FLEXIBLE SOLUTIONS INTERNATIONAL, INC.

CONDENSED INTERIM Consolidated Statements of Stockholders’ Equity

(U.S. Dollars – Unaudited)

Shares Capital
Stock
Capital in
Excess of
Par Value
Accumulated
Earnings
Other
Comprehensive
Loss
Total Non-
Controlling
Interests
Total
Stockholders’
Equity
Balance December 31, 2022 12,426,260 $ 12,426 $ 17,523,345 $ 15,903,964 $ ( 805,799 ) $ 32,633,936 $ 2,605,034 $ 35,238,970
Translation adjustment ( 167,239 ) ( 167,239 ) ( 167,239
Net income 884,369 884,369 80,125 964,494
Common stock issued 9,272 10 13,590 13,600 13,600
Stock-based compensation 185,298 185,298 185,298
Balance March 31, 2023 12,435,532 $ 12,436 $ 17,722,233 $ 16,788,333 $ ( 973,038 ) $ 33,549,964 $ 2,685,159 $ 36,235,123

— See Notes to Unaudited Condensed Interim Consolidated Financial Statements —

6

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2024

(U.S. Dollars - Unaudited)

1. BASIS OF PRESENTATION

These interim condensed consolidated financial statements (“consolidated financial statements”) include the accounts of Flexible Solutions International, Inc. (the “Company”), its wholly-owned subsidiaries Flexible Fermentation Ltd., NanoChem Solutions Inc. (“NanoChem”), Flexible Solutions Ltd., Flexible Biomass LP, FS Biomass Inc., NCS Deferred Corp., Natural Chem SEZC Ltd., InnFlex Holdings Inc., ENP Peru Investments LLC (“ENP Peru”), its 80 % controlling interest in 317 Mendota LLC (“317 Mendota”), and its 65 % controlling interest in ENP Investments, LLC (“ENP Investments”) and ENP Mendota, LLC (“ENP Mendota”). All inter-company balances and transactions have been eliminated upon consolidation. The Company was incorporated on May 12, 1998 in the State of Nevada and in 2019, the Company redomiciled into Alberta, Canada.

In 2022, NanoChem purchased an additional 50 % in ENP Peru, increasing its share to 91.67 %. ENP Investments owned the remaining 8.33 %, of which the Company has a 65 % interest. In 2023, NanoChem purchased the remaining 8.33 % of shares to become sole owner. ENP Peru was previously accounted for under the equity method however, it is now consolidated into the financial statements from the date control was obtained.

In 2023, the Company purchased an 80 % interest in 317 Mendota, a newly incorporated company established to purchase a large manufacturing building. ENP Investments will occupy part of this building, freeing up more space in the building owned by ENP Peru for NanoChem. The Company intends to rent the remainder of the space to suitable tenants. The remaining 20 % non-controlling interest is held by unrelated parties.

The Company and its subsidiaries develop, manufacture and market specialty chemicals which slow the evaporation of water. One product, HEATSAVR®, is marketed for use in swimming pools and spas where its use, by slowing the evaporation of water, allows the water to retain a higher temperature for a longer period of time and thereby reduces the energy required to maintain the desired temperature of the water in the pool. Another product, WATERSAVR®, is marketed for water conservation in irrigation canals, aquaculture, and reservoirs where its use slows water loss due to evaporation. In addition to the water conservation products, the Company also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers (hereinafter referred to as “TPAs”), which are beta-proteins manufactured from the common biological amino acid, L-aspartic. TPAs can be formulated to prevent corrosion and scaling in water piping within the petroleum, chemical, utility and mining industries. TPAs are also used as proteins to enhance fertilizers in improving crop yields and can be used as additives for household laundry detergents, consumer care products and pesticides. The TPA division also manufactures two nitrogen conservation products for agriculture that slows nitrogen loss from fields.

2. SIGNIFICANT ACCOUNTING POLICIES

These consolidated financial statements have been prepared on a historical cost basis, except where otherwise noted, in accordance with accounting principles generally accepted in the United States applicable to a going concern and reflect the policies outlined below.

In the opinion of management, the accompanying unaudited condensed interim consolidated financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company’s financial position as of March 31, 2024 and the results of its operations for the three months then ended. The consolidated balance sheet as of December 31, 2023 is derived from the December 31, 2023 audited financial statements.

(a) Cash and Cash Equivalents .

The Company considers all highly liquid investments purchased with an original or remaining maturity of less than three months at the date of purchase to be cash equivalents. Cash and cash equivalents are maintained with several financial institutions. As of March 31, 2024 and December 31, 2023, the Company did not have any cash equivalents.

(b) Term Deposits .

The Company has five term deposits that are maintained by commercials banks. The first term deposit is for $ 688,126 and matures in April 2024. This deposit pays 4.908 % interest and if withdrawn before maturity, the greater of the loss of accrued interest or $ 150 , plus 1% of the principal shall be levied. The second term deposit is for $ 303,954 and matures in February 2025. This deposit pays 1.3 % interest and if withdrawn before maturity, a penalty may be applied. The third term deposit is for $ 720,982 , matures in May 2024 and pays interest at a rate of 3.00 %. If withdrawn before maturity, the greater of the loss of accrued interest or $ 150 , plus 1% of the principal shall be levied. The fourth term deposit is for $ 1,000,000 and matures in May 2024. This deposit pays 3.85 % and if withdrawn before maturity, the greater of the loss of accrued interest or $ 150 , plus 1% of the principal shall be levied. The fifth term deposit is for $ 310,695 , matures in August 2024 and pays interest at a rate of 3.85 %. If withdrawn before maturity, a penalty may be applied.

(c) Inventories and Cost of Sales .

The Company has three major classes of inventory: completed goods, work in progress and raw materials and supplies. In all classes inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis or weighted average cost formula to inventories in different subsidiaries. Cost of sales includes all expenditures incurred in bringing the goods to the point of sale. Inventory costs and costs of sales include direct costs of the raw material, inbound freight charges, warehousing costs, handling costs (receiving and purchasing) and utilities and overhead expenses related to the Company’s manufacturing and processing facilities. Shipping and handling charges billed to customers are included in revenue (2024 - $ 128,289 ; 2023 - $ 143,173 ). Shipping and handling costs incurred are included in cost of goods sold (2024 - $ 216,503 ; 2023 - $ 255,489 ).

7

(d) Allowance for expected credit losses .

The Company’s expected credit losses are determined through a review using historical credit loss experience; changes in asset specific characteristics, current conditions, and reasonable and supportable future forecasts, among other specific account data, and is performed at least quarterly. The company develops and documents its methodology to determine its allowance for expected credit losses. Risk characteristics used by the Company may include customer mix, knowledge of customers and general economic conditions of the various local economics, among others. Specific account balances are written off when management determines the amounts to be uncollectible. Management has reviewed the balance reserved through the allowance for expected losses and believes it is reasonable.

(e) Property, Equipment, Leaseholds and Intangible Assets .

The following assets are recorded at cost and depreciated using the methods and annual rates shown below:

Manufacturing equipment 20% Declining balance
Office equipment 20% Declining balance
Building and improvements 10% Declining balance
Automobiles Straight-line over 5 years
Technology Straight-line over 10 years
Leasehold improvements Straight-line over lease term
Customer relationships Straight-line over 15 years

(f) Impairment of Long-Lived Assets .

In accordance with FASB Codification Topic 360, Property, Plant and Equipment (ASC 360), the Company reviews long-lived assets, including, but not limited to, property, equipment and leaseholds, patents and other assets, for impairment annually or whenever events or changes in circumstances indicate the carrying amounts of assets may not be recoverable. The carrying value of long-lived assets is assessed for impairment by evaluating operating performance and future undiscounted cash flows of the underlying assets. If the expected future cash flows of an asset is less than its carrying value, an impairment measurement is indicated. Impairment charges are recorded to the extent that an asset’s carrying value exceeds its fair value. Accordingly, actual results could vary significantly from such estimates. There were no impairment charges during the periods presented.

(g) Foreign Currency .

The functional currency of the Company is the U.S. dollar. The functional currency of three of the Company’s subsidiaries is the Canadian dollar. The translation of the Canadian dollar to the reporting currency of the Company, the U.S. dollar, is performed for assets and liabilities using exchange rates in effect at the balance sheet date. Revenue and expense transactions are translated using average exchange rates prevailing during the year. Translation adjustments arising on conversion of the Company’s financial statements from the subsidiary’s functional currency, Canadian dollars, into the reporting currency, U.S. dollars, are excluded from the determination of income (loss) and are disclosed as other comprehensive income in the consolidated statements of income and comprehensive income.

Foreign exchange gains and losses relating to transactions not denominated in the applicable local currency are included in operating income (loss) if realized during the year and in comprehensive income (loss) if they remain unrealized at the end of the year.

(h) Revenue Recognition .

The Company generates revenue primarily from energy and water conservation products and biodegradable polymers, as further discussed in Note 15.

8

The Company follows a five-step model for revenue recognition. The five steps are: (1) identification of the contract(s) with the customer, (2) identification of the performance obligation(s) in the contract(s), (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligation, and (5) recognition of revenue when (or as) the performance obligation is satisfied. The Company has fulfilled its performance obligations when control transfers to the customer, which is generally at the time the product is shipped since risk of loss is transferred to the purchaser upon delivery to the carrier. For shipments which are free-on-board shipping point, the Company has elected to account for shipping and handling activities as a fulfillment cost rather than as an additional promised service and performance obligation.

Since the Company’s inception, product returns have been insignificant; therefore, no provision has been established for estimated product returns.

Deferred revenues consist of products sold to distributors with payment terms greater than the Company’s customary business terms due to lack of credit history or operating in a new market in which the Company has no prior experience. The Company defers the recognition of revenue until the criteria for revenue recognition has been met and payments become due or cash is received from these distributors.

(i) Stock Issued in Exchange for Services .

The Company’s common stock issued in exchange for services is valued at estimated fair market value based upon trading prices of the Company’s common stock on the dates of the stock transactions. The corresponding expense of the services rendered is recognized over the period that the services are performed.

(j) Stock-based Compensation .

The Company recognizes compensation expense for all share-based payments in accordance with FASB Codification Topic 718, Compensation — Stock Compensation (ASC 718). Under the fair value recognition provisions of ASC 718, the Company recognizes share-based compensation expense, net of an estimated forfeiture rate, over the requisite service period of the award.

The fair value at grant date of stock options is estimated using the Black-Scholes option-pricing model. Compensation expense is recognized on a straight-line basis over the stock option vesting period based on the estimated number of stock options that are expected to vest. Shares are issued from treasury upon exercise of stock options.

(k) Other Comprehensive Income .

Other comprehensive income refers to revenues, expenses, gains and losses that under generally accepted accounting principles are included in comprehensive income, but are excluded from net income as these amounts are recorded directly as an adjustment to stockholders’ equity. The Company’s other comprehensive income is comprised only of unrealized foreign exchange gains and losses related to the translation of subsidiaries’ functional currency into the reporting currency.

(l) Income Per Share .

Basic earnings per share is computed by dividing income available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted earnings per share are calculated giving effect to the potential dilution of the exercise of options and warrants. Common equivalent shares, composed of incremental common shares issuable upon the exercise of stock options and warrants are included in diluted net income per share to the extent that these shares are dilutive. Common equivalent shares that have an anti-dilutive effect on net income per share have been excluded from the calculation of diluted weighted average shares outstanding for the three months ended March 31, 2024 and 2023.

9

(m) Use of Estimates .

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and would impact the results of operations and cash flows.

Estimates and underlying assumptions are reviewed at each period end. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Significant areas requiring the use of management estimates include assumptions and estimates relating to the valuation of goodwill and intangible assets, valuation of assets acquired at fair value, asset impairment analysis, share-based payments, valuation allowances for deferred income tax assets, determination of useful lives of property, equipment and leaseholds and intangible assets, recoverability of accounts receivable, recoverability of investments, discount rates for right of use assets and the costing and recoverable value of inventory.

(n) Fair Value of Financial Instruments .

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs described below, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.

Level 1 – Quoted prices in active markets for identical assets or liabilities.
Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 — Unobservable inputs that are supported by little or no market activity which is significant to the fair value of the assets or liabilities.

The fair values of cash, term deposits, accounts receivable, accounts payable, accrued liabilities and the short term line of credit for all periods presented approximate their respective carrying amounts due to the short term nature of these financial instruments.

The fair value of the long term debt and lease liabilities for all periods presented approximate their respective carrying amounts due to these financial instruments being at market rates.

(o) Contingencies .

Certain conditions may exist as of the date the consolidated financial statements are issued which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

10

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Legal fees associated with loss contingencies are expensed as incurred. The Company is not aware of any contingencies at the date of these consolidated financial statements.

(p) Income Taxes .

Income taxes are computed by multiplying the Company’s taxable net income by the Company’s effective tax rates. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss carry-forwards, if any. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided to reduce the carrying amount of deferred income tax assets if it is considered more likely than not that some portion, or all, of the deferred income tax assets will not be realized.

In accordance with FASB Codification Topic 740, Income taxes (ASC 740) under the liability method, it is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At March 31, 2024, the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected. Interest and penalties associated with the Company’s tax positions are recorded as interest expense in the consolidated statements of income and comprehensive income.

(q) Risk Management .

The Company’s credit risk is primarily attributable to its accounts receivable. The amounts presented in the accompanying consolidated balance sheets are net of allowances for doubtful accounts, estimated by the Company’s management based on prior experience and the current economic environment. The Company is exposed to credit-related losses in the event of non-payment by customers. Credit exposure is minimized by dealing with only credit worthy counterparties. Revenue for the Company’s three primary customers totaled $ 5,106,905 ( 55 %) for the three months ended March 31, 2024 (2023 - $ 4,366,106 or 44 %). Accounts receivable for the Company’s three primary customers totaled $ 7,843,766 ( 60 %) at March 31, 2024 (December 31, 2023 - $ 6,561,164 or 67 %). See Note 4 for allowance for doubtful accounts, all unrelated to our primary customers.

The credit risk on cash is limited because the Company limits its exposure to credit loss by placing its cash with major financial institutions. The Company maintains cash balances at financial institutions which at times exceed federally insured amounts. The Company has not experienced any losses in such accounts.

The Company is exposed to foreign risk to the extent that market value rate fluctuations materially differ for financial assets and liabilities denominated in foreign currencies.

In order to manage its exposure to foreign exchange risks, the Company closely monitors the fluctuations in the foreign currency exchange rates and the impact on the value of cash, accounts receivable, and accounts payable and accrued liabilities. The Company has not hedged its exposure to currency fluctuations.

The Company is exposed to interest rate risk to the extent that the fair value or future cash flows for financial liabilities will fluctuate as a result of changes in market interest rates. The Company is exposed to interest rate risk on its long-term debt subject to fixed long-term interest rates.

In order to manage its exposure to interest rate risk, the Company closely monitors fluctuations in market interest risks and will refinance its long-term debt where possible to obtain more favourable rates.

11

(r) Equity Method Investment .

The Company accounts for investments using the equity method of accounting if the investment provides the Company the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company’s ownership interest in the voting stock of the investee ranges between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment is initially recorded at cost in the consolidated balance sheets under other assets and adjusted for dividends received and the Company’s share of the investee’s earnings or losses together with other-than-temporary impairments which are recorded through other income (loss), net in the consolidated statements of operations and comprehensive income (loss).

(s) Goodwill and Intangible Assets .

Goodwill represents the excess of the purchase price of an acquired entity over the amounts assigned to the assets acquired and liabilities assumed. Goodwill is not amortized, but is reviewed for impairment annually or more frequently if certain impairment conditions arise. The Company performs an annual goodwill impairment review in the fourth quarter of each year at the reporting unit level. The evaluation begins with a qualitative assessment of the factors that could impact the significant inputs used to estimate fair value. If after performing the qualitative assessment, it is determined that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, including goodwill, then no further analysis is necessary. However, if the results of the qualitative test are unclear, the Company performs a quantitative test, which involves comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses an income-based valuation method, determining the present value of future cash flows, to estimate the fair value of a reporting unit. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and no further analysis is necessary. If the fair value of the reporting unit is less than its carrying amount, goodwill impairment would be recognized equal to the amount of the carrying value in excess of the reporting unit’s fair value, limited to the total amount of goodwill allocated to the reporting unit.

Intangible assets primarily include trademarks and trade secrets with indefinite lives and customer-relationships with finite lives. Intangible assets with indefinite lives are not amortized but are tested for impairment on an annual basis, or more frequently if indicators of impairment are present. Indefinite lived intangible assets are assessed using either a qualitative or a quantitative approach. The qualitative assessment evaluates factors including macro-economic conditions, industry and company-specific factors, legal and regulatory environments, and historical company performance in assessing fair value. If it is determined that it is more likely than not that the fair value of the intangible asset is less than its carrying value, a quantitative test is then performed. Otherwise, no further testing is required. When using a quantitative approach, the Company compares the fair value of the intangible asset to its carrying amount. If the estimated fair value of the intangible asset is less than the carrying amount of the intangible asset, impairment is indicated, requiring recognition of an impairment charge for the differential.

In accordance with FASB Codification Topic 350, Intangibles – Goodwill and Other, (ASC 350), qualitative assessments of goodwill and indefinite-lived intangible assets were performed at December 31, 2023. Based on the results of the assessment, it was determined that it is more likely than not the reporting unit, customer lists and trademarks had a fair value in excess of their carrying amounts. Accordingly, no further impairment testing was completed and no impairment charges related to goodwill or indefinite-lived intangibles were recognized during the three months ended March 31, 2024.

Finite-lived intangible assets are amortized on a straight-line basis over their estimated useful lives. The Company reviews for impairment indicators of finite-lived intangibles and other long-lived assets as described in the “Impairment of Long Lived Assets” significant accounting policy.

(t) Recent Accounting Pronouncements .

The Company has implemented all applicable new accounting pronouncements that are in effect. Those pronouncements did not have any material impact on the consolidated financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

12

3. LEASES

Leases are evaluated and classified as either operating or finance leases by the lessee and as either operating, sales-type or direct financing leases by the lessor. For leases with terms greater than 12 months, the Company records the related right-of-use (“ROU”) asset and lease obligation at the present value of lease payments over the term. Leases may include fixed rental escalation clauses, renewal options and / or termination options that are factored into the determination of lease payments when appropriate. The Company’s operating leases are included in ROU assets, lease liabilities-current portion and lease liability-long term portion in the accompanying consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. The Company’s leases do not usually provide a readily determinable implicit rate; therefore, an estimate of the Company’s incremental borrowing rate is used to discount the lease payments based on information available at the lease commencement date. The discount rate used was 5.5 %.

In March 2024, the Company consolidated NanoChem operations into the Peril, IL locations and terminated the lease in Naperville, IL. The Company had to pay a penalty of $ 35,910 and forfeited the $ 5,440 security deposit to terminate the lease early and incurred a loss of $ 41,350 on early termination of the lease. The table below summarizes the right-of-use asset and lease liability for the periods ended March 31, 2024 and December 31, 2023.

Right of Use Assets
Balance at December 31, 2022 $ 167,222
Depreciation ( 51,929 )
Balance at December 31, 2023 $ 115,293
Depreciation ( 13,694 )
Early termination of lease ( 101,599 )
Balance at March 31, 2024 $ -
Lease Liability
Balance at December 31, 2022 $ 167,222
Lease interest expense 6,151
Payments ( 58,080 )
Balance at December 31, 2023 $ 115,293
Lease interest expense 1,186
Payments ( 14,880 )
Early termination of lease ( 101,599 )
Balance at March 31, 2024 $ -

4. ACCOUNTS RECEIVABLE

March 31, 2024 December 31, 2023
Accounts receivable $ 13,281,820 $ 10,133,249
Allowances for doubtful accounts ( 289,277 ) ( 290,193 )
Total accounts receivable $ 12,992,543 $ 9,843,056

5. INVENTORIES

March 31, 2024 December 31, 2023
Completed goods $ 2,139,797 $ 2,682,158
Raw materials and supplies 8,319,459 8,452,731
Total inventory $ 10,459,256 $ 11,134,889

13

6. PROPERTY, EQUIPMENT AND LEASEHOLDS

March 31, 2024 Accumulated March 31, 2024
Cost Depreciation Net
Buildings and improvements $ 12,408,992 $ 4,049,352 $ 8,359,640
Automobiles 196,255 147,232 49,023
Office equipment 122,161 111,825 10,336
Manufacturing equipment 10,424,369 6,016,720 4,407,649
Land 440,592 440,592
Leasehold improvements 88,872 88,872
Technology 100,819 100,819
$ 23,782,060 $ 10,514,820 $ 13,267,240

December 31, 2023 Accumulated December 31, 2023
Cost Depreciation Net
Buildings and improvements $ 12,341,605 $ 3,896,887 $ 8,444,718
Automobiles 196,255 140,040 56,215
Office equipment 177,623 165,048 12,575
Manufacturing equipment 10,017,466 5,799,779 4,217,687
Land 440,592 440,592
Leasehold improvements 88,872 88,872
Technology 103,292 103,292
$ 23,365,705 $ 10,193,918 $ 13,171,787

Amount of depreciation expense for three months ended March 31, 2024 was: $ 382,669 (2023 - $ 302,810 ) and is included in cost of sales in the unaudited interim condensed consolidated statements of income and comprehensive income.

In January 2024, the Company lost power during a winter storm and some frozen pipes caused damage at two different locations. Insurance was in place and repairs are currently being made.

7. GOODWILL AND INTANGIBLE ASSETS

Goodwill
Balance as of December 31, 2022 and 2023 and March 31, 2024 $ 2,534,275
Indefinite Lived Intangible Assets
Balance as of December 31, 2022 and 2023 and March 31, 2024 $ 770,000

Goodwill relates to the acquisition of ENP Investments. Indefinite lived intangible assets consist of trade secrets and trademarks related to the acquisition of ENP Investments.

Definite Life Intangible Assets
Balance as of December 31, 2022 1,670,000
Amortization ( 160,000 )
Balances as of December 31, 2023 $ 1,510,000
Amortization ( 40,000 )
Balances as of March 31, 2024 $ 1,470,000

14

The amount of amortization for three months ended March 31, 2024 was $ 40,000 (2023 - $ 40,000 ) and was included in cost of sales in the unaudited interim condensed consolidated statements of income and comprehensive income.

Definite lived intangible assets consist of customer relationships and software related to the acquisition of ENP Investments.

Estimated amortization expense over the next five years is as follows:

2024 $ 160,000
2025 160,000
2026 160,000
2027 160,000
2028 160,000

8. LONG TERM DEPOSITS

The Company has security deposits that are long term in nature which consist of damage deposits held by landlords and deposits held by various vendors for equipment purchases.

March 31, 2024 December 31, 2023
Long term deposits $ 840,592 $ 824,254

9. INVESTMENTS

( a ) T he Company previously held a 50 % ownership interest in ENP Peru, split between NanoChem ( 41.67 %) and ENP Investments ( 8.33 %), which was acquired in fiscal 2016. ENP Peru is located in Illinois and leases warehouse space to other entities in the Company. In June 2022, NanoChem acquired an additional 50 % ownership interest at a cost of $ 506,659 paid through a new $ 259,000 mortgage and cash on hand. The 35 % non-controlling interest of the 8.33 % owned by ENP Investments is included in non-controlling interest in these consolidated financial statements. The Company’s investment in ENP Peru was previously accounted for using the equity method, however, it is now consolidated into the consolidated financial statements from the date control was obtained. In June 2023, NanoChem purchased the remaining 8.33 % of ENP Peru from ENP Investments to become full owner.

It was determined that ENP Peru did not meet the definition of a business in accordance with FASB Codification Topic 805, Business Combinations (ASC 805) , and the acquisition was accounted for as an asset acquisition. The following table summarizes the final purchase price allocation of the consideration paid to the respective fair values of the assets acquired and liabilities assumed in ENP Peru as of the acquisition date. The gain on acquisition of ENP Peru represents a gain on remeasurement of the Company’s equity method investment immediately prior to the acquisition date.

Purchase consideration $ 506,659
Assets acquired:
Cash 7,330
Building 3,750,000
Land 150,000
Liabilities assumed:
Deferred tax liability ( 174,582 )
Long term debt ( 2,849,500 )
Total identifiable net assets: 883,248
Excess of assets acquired over consideration 376,589
Less investment eliminated upon consolidation ( 41,538 )
Gain on acquisition of ENP Peru $ 335,051

A summary of the Company’s investment follows:

Balance, December 31, 2022 22,642
Return of equity ( 8,750 )
Gain in equity method investment 27,646
Investment eliminated upon consolidation ( 41,538 )
Balance, December 31, 2023 and March 31, 2024 $ -

15

( b ) In December 2018, the Company invested $ 200,000 in Applied Holding Corp. (“Applied”). Applied is a captive insurance company and the Company received a non-convertible promissory note for its investment which becomes due in 2021 but may be extended with notice for a maximum of two years. During the year ended December 31, 2021, the Company entered an agreement with Applied to extend the maturity date of this promissory note to December 2023 . In October 2023, the Company received the payment of $ 200,000 to settle the promissory note and the balance of this investment at March 31, 2024 is $ nil (December 31, 2023 - $ nil ). In accordance with FASB Codification Topic 321, Investments – Equity Securities ( ASC 321), the Company has elected to account for this investment at cost.

( c ) In December 2018, the Company invested $ 500,000 in Trio Opportunity Corp. (“Trio”), a privately held entity and a further $ 470,000 was invested in April 2023. Trio is a real estate investment vehicle and the Company received 97,000 non-voting Class B shares at $ 10.00 /share. In accordance with ASC 321, the Company has elected to account for this investment at cost.

(d) In January 2019, the Company invested in a Florida based LLC that is engaged in international sales of fertilizer additives. The Company accounts for this investment using the equity method of accounting. According to the operating agreement, the Company has a 50 % interest in the profit and loss of the Florida based LLC but does not have control. A summary of the Company’s investment follows:

Balance, December 31, 2022 $ 3,758,895
Gain in equity method investment 505,065
Return of equity ( 200,000 )
Balance, December 31, 2023 4,063,960
Gain in equity method investment 182,201
Return of equity ( 327,000 )
Balance, March 31, 2024 $ 3,919,161

Summarized profit and loss information related to the equity accounted investment is as follows:

Three months
ended
March 31, 2024
Three months
ended
March 31, 2023
Net sales $ 3,319,582 $ 3,447,125
Gross profit 1,014,988 965,052
Net income $ 364,403 $ 139,990

During the three months ended March 31, 2024, the Company had sales of $ 2,299,938 (2023 - $ 1,778,897 ) to the Florida Based LLC, of which $ 1,723,833 is included within Accounts Receivable as at March 31, 2024 (December 31, 2023 - $ 2,073,813 ).

16

(e) In December 2020, the Company invested $ 500,000 in Lygos Inc. (“Lygos”), a privately held entity, under a Simple Agreement for Future Equity (“SAFE”) agreement. Lygos is a company developing a sustainable aspartic acid microbe strain. In 2021, the Company made a second SAFE investment of $ 500,000 for a total of $ 1,000,000 . In accordance with ASC 321, the Company has elected to account for this investment at cost.

10. SHORT-TERM LINE OF CREDIT

( a ) In June 2023, ENP Investments renewed the line of credit with Stock Yards Bank and Trust (“Stock Yards”), increasing the limit by $ 500,000 from the previous line of credit. The revolving line of credit is for an aggregate amount of up to the lesser of (i) $ 4,500,000 , or (ii) 50-80% of eligible domestic accounts receivable plus 50 % of inventory, capped at $ 2,000,000 . Interest on the unpaid principal balance of this loan will be calculated using the greater of prime or 8.25%. The interest rate at March 31, 2024 is 8.5 % (December 31, 2023 - 8.5 %).

The revolving line of credit contains customary affirmative and negative covenants, including the following: compliance with laws, provisions of financial statements and periodic reports, payment of taxes, maintenance of inventory and insurance, maintenance of operating accounts at Stock Yards, Stock Yard’s access to collateral, formation or acquisition of subsidiaries, incurrence of indebtedness, dispositions of assets, granting liens, changes in business, ownership or business locations, engaging in mergers and acquisitions, making investments or distributions and affiliate transactions. NanoChem is a guarantor of 65 % of all the principal and other loan costs not to exceed $ 2,925,000 . The non-controlling interest is the guarantor of the remaining 35 % of all the principal and other loan costs not to exceed $ 1,575,000 . As of March 31, 2024, ENP Investments was in compliance with all loan covenants.

To secure the repayment of any amounts borrowed under the revolving line of credit, the Company granted Stock Yards a security interest in substantially all of the assets of ENP Investments, exclusive of intellectual property assets.

Short-term borrowings outstanding under the revolving line as of March 31, 2024 were $ 3,259,935 (December 31, 2023 - $ 1,810,479 ).

(b) In June 2023, the Company renewed the line of credit with Stock Yards Bank and Trust (“Stock Yards”). The revolving line of credit is for an aggregate amount of up to the lesser of (i) $ 4,000,000 , or (ii) 80 % of eligible domestic accounts receivable and certain foreign accounts receivable plus 50 % of inventory, capped at $ 2,000,000 . Interest on the unpaid principal balance of this loan will be calculated using the greater of prime or 8.25%. The interest rate at March 31, 2024 is 8.5 % (December 31, 2023 - 8.5 %).

The revolving line of credit contains customary affirmative and negative covenants, including the following: compliance with laws, provision of financial statements and periodic reports, payment of taxes, maintenance of inventory and insurance, maintenance of operating accounts at Stock Yards, Stock Yards access to collateral, formation or acquisition of subsidiaries, incurrence of indebtedness, dispositions of assets, granting liens, changes in business, ownership or business locations, engaging in mergers and acquisitions, making investments or distributions and affiliate transactions. The covenants also require that the Company maintain a minimum ratio of qualifying financial assets to the sum of qualifying financial obligations. As of March 31, 2024, the Company was in compliance with all loan covenants.

To secure repayment of any amounts borrowed under the revolving line of credit, the Company granted Stock Yards a security interest in substantially all of the assets of NanoChem, exclusive of intellectual property assets.

Short-term borrowings outstanding under the revolving line as of March 31, 2024 were $ nil (December 31, 2023 were $ nil ).

11. LONG TERM DEBT

(a) In January 2020, ENP Mendota refinanced its mortgage and signed a loan for $ 450,000 with Stock Yards to be repaid over 10 years with monthly installments plus interest. Interest for the first five years is at 4.35 % and it will be adjusted for the last five years to the Cincinnati Federal Home Bank Loan 5 year fixed index plus 4.5 %. Interest expense for the three months ended March 31, 2024 was $ 4,373 (2023 - $ 4,501 ). The balance owing at March 31, 2024 was $ 396,371 (December 31, 2023 - $ 399,269 ).

17

To secure repayment of any amounts borrowed under the mortgage, the Company granted Stock Yards a security interest in real property under the mortgage and all rents on said property.

(b) In June 2022, NanoChem signed a loan for $ 1,935,000 with Stock Yards with an interest rate of 4.90 % to be repaid over three years with equal monthly payments including interest. The funds were used to replace the loans at Midland for the purchase of the 65 % interest in ENP Investments and the new manufacturing equipment. Interest expense for the three months ended March 31, 2024 was $ 11,801 (2023 - $ 19,409 ). The balance owing at March 31, 2024 was $ 842,828 (December 31, 2023 - $ 1,004,748 ).

(c) In January 2020 ENP Peru signed a $ 3,000,000 loan with an interest rate 4.35 % to be repaid over ten years with equal monthly payments including interest. Upon the purchase of the remainder of ENP Peru in June 2022, the Company assumed the first mortgage at Stock Yards with a balance of $ 2,849,500 . Interest expense for the three months ended March 31, 2024 was $ 30,003 (2023 - $ 30,530 ). The balance owing at March 31, 2024 was $ 2,717,683 (December 31, 2023 - $ 2,737,232 ).

(d) In June 2022, ENP Peru obtained a second mortgage for $ 259,000 with Stock Yards to be repaid over 10 years with monthly installments plus interest with an interest rate of 5.4 %. Interest expense for the three months ended March 31, 2024 was $ 3,409 (2023 - $ 3,452 ). The balance owing at March 31, 2024 was $ 248,658 (December 31, 2023 - $ 250,207 ).

(e) In December 2022, NanoChem signed a three year loan for up to $ 2,000,000 with Stock Yards with an interest rate of 6.5 %. Interest only payments are required for the first 18 months with interest and principal being paid in the last 18 months. The funds are being used to purchase new manufacturing equipment. Interest expense for the three months ended March 31, 2024 was $ 23,525 (2022 - $ 15,917 ). The balance owing at March 31, 2024 was $ 1,533,004 (December 31, 2023 - $ 1,475,188 ).

(f) In June 2023, 317 Mendota signed a five year loan for up to $ 3,240,000 with Stock Yards to purchase a building and any necessary renovations. Interest only payments are required for the first 12 months with interest and principal being paid the remaining four years and a lump sum due in June 2028. Interest expense for the three months ended March 31, 2024 was $ 46,886 (2023 - $ nil ). The balance owing at March 31, 2024 was $ 2,248,292 (December 31, 2023 - $ 2,248,292 ).

As of March 31, 2024, Company was in compliance with all loan covenants.

Continuity March 31, 2024 December 31, 2023
Balance, January 1 $ 8,114,936 $ 6,154,077
Plus: Proceeds from loans 57,816 2,686,682
Less: Payments on loan ( 185,916 ) ( 725,823 )
Balance, end of period $ 7,986,836 $ 8,114,936

Outstanding balance March 31, 2024 December 31, 2023
a) Long term debt – Stock Yards Bank & Trust $ 396,371 $ 399,269
b) Long term debt – Stock Yards Bank & Trust 842,828 1,004,748
c) Long term debt – Stock Yards Bank & Trust 2,717,683 2,737,232
d) Long term debt – Stock Yards Bank & Trust 248,658 250,207
e) Long term debt – Stock Yards Bank & Trust 1,533,004 1,475,188
f) Long term debt – Stock Yards Bank & Trust 2,248,292 2,248,292
Long-term debt 7,986,836 8,114,936
Less: current portion ( 1,665,440 ) ( 1,281,632 )
Long-term debt non current $ 6,321,396 $ 6,833,304

18

12. STOCK OPTIONS

The Company has a stock option plan (“Plan”). The purpose of this Plan is to provide additional incentives to key employees, officers, directors and consultants of the Company and its subsidiaries in order to help attract and retain the best available personnel for positions of responsibility and otherwise promote the success of the Company’s business. It is intended that options issued under this Plan constitute non-qualified stock options. The general terms of awards under the option plan are that 100 % of the options granted will vest the year following the grant unless a executive employee is granted a multi-year stock option grant where an equal amount vests over the next 5 years. The maximum term of options granted is 5 years and the exercise price for all options are issued for not less than fair market value at the date of the grant.

The following table summarizes the Company’s stock option activities for the year ended December 31, 2023 and the three-month period ended March 31, 2024:

Number of shares

Exercise price

per share

Weighted average

exercise price

Balance, December 31, 2022 1,686,000 $ 1.70 4.13 $ 3.26
Cancelled or expired ( 564,000 ) $ 3.46 4.13 $ 3.55
Exercised ( 8,000 ) $ 1.70 $ 1.70
Balance, December 31, 2023 1,114,000 $ 1.75 3.61 $ 3.13
Granted 950,000 $ 2.00 $ 2.00
Cancelled or expired ( 103,000 ) $ 1.75 3.61 $ 2.06
Exercised ( 15,000 ) $ 1.75 $ 1.75
Balance, March 31, 2024 1,946,000 $ 2.00 3.61 $ 2.65
Exercisable, March 31, 2024 814,000 $ 2.00 3.61 $ 2.86

The weighted-average remaining contractual life of outstanding options is 3.75 years.

The fair value of each option grant is calculated using the following weighted average assumptions:

2024
Expected life – years 3.0
Interest rate 3.893 4.22 %
Volatility 59.72 60.35 %
Weighted average fair value of options granted $ 0.71 0.79

During the three months ended March 31, 2024, the Company granted 56,000 (2023 – nil ) stock options to consultants and has applied ASC 718 using the Black-Scholes option-pricing model, which resulted in expenses of $ 9,940 (2023 - $ nil ). Options granted in other years resulted in additional expenses of $ nil (2023 – $ 62,241 ). During the three months ended March 31, 2024, employees were granted 894,000 (2023 – nil ) stock options, which resulted in expenses of $ 199,687 (2023 – $ nil ). Options granted in other years resulted in additional expenses in the amount of $ 43,730 for employees during the three months ended March 31, 2024 (2023 - $ 328,769 ). There were 15,000 employee and nil consultant stock options exercised during the three months ended March 31, 2024 (2023 – 8,000 employee; nil consultant).

As of March 31, 2024, there was approximately $ 822,813 of compensation expense related to non-vested awards. This expense is expected to be recognized over a weighted average period of 2.3 years.

The aggregate intrinsic value of vested options outstanding at March 31, 2024 is $ nil (2023 – $ 161,430 ). The intrinsic value of options exercised during the three months ended March 31, 2024 was $ 720 (2023 - $ 11,520 ).

19

13. CAPITAL STOCK

During the three months ended March 31, 2024, 15,000 shares were issued upon the exercise of employee stock options (2023 – 8,000 ).

During the three months ended March 31, 2023, the Company issued 1,272 shares to a consultant for services rendered, resulting in an expense of $ 4,070 on the unaudited interim condensed consolidated statements of income and comprehensive income for the three months ended March 31, 2023.

During 2023, the Company announced a special dividend of $ 0.05 per share that was paid on May 16, 2023 to shareholders.

14. NON-CONTROLLING INTERESTS

( a ) ENP Investments is a limited liability corporation (“LLC”) that manufactures and distributes golf, turf and ornamental agriculture products in Mendota, Illinois. The Company owns a 65 % interest in ENP Investments through its wholly-owned subsidiary NanoChem. An unrelated party (“NCI”) owns the remaining 35 % interest in ENP Investments. ENP Mendota is a wholly owned subsidiary of ENP Investments. ENP Mendota is a LLC that leases warehouse space. For financial reporting purposes, the assets, liabilities and earnings of both of the LLC’s are consolidated into these financial statements. The NCI’s ownership interest in ENP Investments is recorded in non-controlling interests in these consolidated financial statements. The non-controlling interest represents NCI’s interest in the earnings and equity of ENP Investments. ENP Investments is allocated to the TPA segment.

ENP Investments makes cash distributions to its equity owners based on formulas defined within its Ownership Interest Purchase Agreement dated October 1, 2018. Distributions are defined in the Ownership Interest Purchase Agreement as cash on hand to the extent it exceeds current and anticipated long-term and short-term needs, including, without limitation, needs for operating expenses, debt service, acquisitions, reserves, and mandatory distributions, if any.

From the effective date of acquisition onward, the minimum distributions requirements under the Ownership Interest Purchase Agreement were satisfied. The total distribution from the effective date of acquisition onward was $ 3,225,957 .

Balance, December 31, 2022 $ 2,605,034
Distribution ( 719,439 )
Non-controlling interest share of income 1,015,604
Balance, December 31, 2023 2,901,199
Non-controlling interest share of income 80,460
Balance, March 31, 2024 $ 2,981,659

During the three months ended March 31, 2024, the Company had sales of $ 1,291,426 (2023 - $ 1,098,948 ) to NCI, of which $ 5,381,282 is included in Accounts Receivable as of March 31, 2024 (December 31, 2023 – $ 4,225,028 ).

b ) 317 Mendota is a LLC that owns real estate that the Company intends to occupy part of while renting out the excess. The Company owns a 80 % interest in 317 Mendota and an unrelated party (“317 NCI”) owns the remaining 20 % interest in 317 Mendota. For financial reporting purposes, the assets, liabilities and earnings of 317 Mendota are consolidated into these financial statements. The 317 NCI’s ownership interest in 317 Mendota is recorded in non-controlling interests in these consolidated financial statements. The non-controlling interest represents 317 NCI’s interest in the earnings and equity of 317 Mendota. 317 Mendota is allocated to the TPA segment as that is the intended use of the building.

Balance, December 31, 2022 $ -
Acquisition 200,000
Non-controlling interest share of income ( 35,483 )
Balance, December 31, 2023 164,517
Non-controlling interest share of income ( 21,477 )
Balance, March 31, 2024 $ 143,040

20

15. SEGMENTED, SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY

The Company operates in two segments:

(a) Energy and water conservation products (as shown under the column heading “EWCP” below), which consists of a (i) liquid swimming pool blankets which save energy and water by inhibiting evaporation from the pool surface, and (ii) food-safe powdered form of the active ingredient within the liquid blankets and which are designed to be used in still or slow moving drinking water sources.

(b) Biodegradable polymers, also known as TPA’s (as shown under the column heading “BCPA” below), used by the petroleum, chemical, utility and mining industries to prevent corrosion and scaling in water piping. This product can also be used in detergents to increase biodegradability and in agriculture to increase crop yields by enhancing fertilizer uptake.

The third product line is nitrogen conservation products used for the agriculture industry. These products decrease the loss of nitrogen fertilizer after initial application and allows less fertilizer to be used. These products are made and sold by the Company’s TPA division.

The accounting policies of the segments are the same as those described in Note 2, Significant Accounting Policies . The Company evaluates performance based on profit or loss from operations before income taxes, not including nonrecurring gains and losses and foreign exchange gains and losses

The Company’s reportable segments are strategic business units that offer different, but synergistic products and services. They are managed separately because each business requires different technology and marketing strategies.

Three months ended March 31, 2024:

EWCP BCPA Consolidated
Sales $ 41,608 $ 9,183,264 $ 9,224,872
Interest expense - 175,266 175,266
Depreciation 3,883 418,786 422,669
Income tax expense 34,940 229,238 264,178
Segment profit 18,540 438,685 457,225
Segment assets 3,664,387 53,897,000 57,561,387
Expenditures for segment assets - ( 477,350 ) ( 477,350 )

Three months ended March 31, 2023:

EWCP BCPA Consolidated
Sales $ 80,660 $ 9,776,857 $ 9,847,517
Interest expense - 134,870 134,870
Depreciation 4,279 360,905 365,184
Income tax expense 915 298,862 299,777
Segment profit ( 151,728 ) 1,116,222 964,494
Segment assets 2,858,968 50,079,080 52,938,048
Expenditures for segment assets - ( 213,060 ) ( 213,060 )

21

Sales by territory are shown below:

Three months
ended
March 31, 2024
Three months
ended
March 31, 2023
Canada $ 88,478 $ 116,680
United States and abroad 9,136,394 9,730,837
Total $ 9,224,872 $ 9,847,517

The Company’s long-lived assets (property, equipment, leaseholds, right of use assets, intangibles, and goodwill) are located in Canada and the United States as follows:

March 31, 2024 December 31, 2023
Canada $ 135,299 $ 142,577
United States 17,906,216 17,958,778
Total $ 18,041,515 $ 18,101,355

Three primary customers accounted for $ 5,106,905 ( 55 %) of sales during the three-month period ended March 31, 2024 (2023 - $ 4,366,106 or 44 %).

16. COMPARATIVE FIGURES .

Certain of the comparative figures have been reclassified to conform with the current period’s presentation.

17. SUBSEQUENT EVENTS

In April 2024, the Company announced a special dividend of $ 0.10 per share that to be paid on May 16, 2024 to shareholders of record on April 30, 2024.

22

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Overview

The Company manufactures and markets biodegradable polymers which are used in the oil, gas and agriculture industries. The Company also develops, manufactures and markets specialty chemicals that slow the evaporation of water.

Results of Operations

We have three product lines.

The first is a chemical (“EWCP”) used in swimming pools and spas. The product forms a thin, transparent layer on the water’s surface. The transparent layer slows the evaporation of water, allowing the water to retain a higher temperature for a longer period of time thereby reducing the energy required to maintain the desired temperature of the water. A modified version of EWCP can also be used in reservoirs, potable water storage tanks, livestock watering pods, canals, and irrigation ditches for the purpose of reducing evaporation.

The second product, biodegradable polymers (“TPAs”), is used by the petroleum, chemical, utility and mining industries to prevent corrosion and scaling in water piping. TPAs can also be used to increase biodegradability in detergents and in the agriculture industry to increase crop yields by enhancing fertilizer uptake.

The third product line is nitrogen conservation products used for the agriculture industry. These products decrease the loss of nitrogen fertilizer after initial application and allows less fertilizer to be used. These products are made and sold by the Company’s TPA division.

Material changes in the Company’s Statement of Operations for three months ended March 31, 2024 compared to the same period in the prior year are discussed below:

Three Months ended March 31, 2024

Item

Increase (I) or

Decrease (D)

Reason
Sales
EWCP products D Decreased customer orders.
TPA products D Decreased customer orders.
Insurance I Prior year increase in assets and in sales resulted in higher insurance costs.
Interest expense I Increased debt resulted in increased interest expense.
Office and Miscellaneous I

One time moving costs associated with closing the Naperville location.

Research I

New product development.

Consulting I

Increased reliance on consultants instead of full time employees.

Utilities I

Addition of real estate not yet rented out.

Advertising and promotion I Increased outreach to customers and prospects.

Lease termination fee

I One time cost incurred terminating lease in Naperville, IL.
Investor relations D Reduced shares traded and filings required in 2023 did not reoccur in 2024.
Currency exchange D Currency exchange decreased as a result of movements in the US / Canadian dollar exchange rate and its effects on US dollar cash balances and US dollar payables held by the Company’s Canadian subsidiaries.

Three primary customers accounted for 55% of the Company’s sales during the three months ended March 31, 2024 (2023 - 44%). The amount of revenue (all from the sale of TPA products) attributable to each customer is shown below.

Three Months Ended March 31,
2024 2023
Company A $ 1,291,426 $ 1,098,948
Company B $ 2,299,938 $ 1,778,897
Company C $ 1,515,541 $ 1,488,260

23

Customers with balances greater than 10% of our receivables as of March 31, 2024 and 2023 are shown below:

March 31,
2024 2023
Company A $ 5,381,282 $ 4,654,000
Company B $ 1,723,833 $ 1,470,846

Other factors that will most significantly affect future operating results will be:

the sale price of crude oil which is used in the manufacture of aspartic acid we import from China. Aspartic acid is a key ingredient in our TPA products;
activity in the oil and gas industry, as we sell our TPA products to oil and gas companies;
drought conditions, since we also sell our TPA products to farmers; and

Other than the foregoing we do not know of any trends, events or uncertainties that have had, or are reasonably expected to have, a material impact on our revenues or expenses.

Capital Resources and Liquidity

The Company’s sources and (uses) of cash for the three months ended March 31, 2024 and 2023 are shown below:

2024 2023
Cash provided (used) by operations (532,251 ) (228,229 )
Long term deposits (21,778 ) (342,747 )
Proceeds of equity investment 327,000 -
Purchase of equipment (478,123 ) (213,060 )
Borrowings from short term line of credit 1,449,456 844,913
Loan repayments (185,916 ) (177,639 )
Proceeds of loans 57,816
Lease payments (50,790 ) (14,520 )
Proceeds from sale of common stock 26,250 13,600
Changes in exchange rates 27,223 (167,239 )

The Company has sufficient cash resources to meets its future commitments and cash flow requirements for the coming year. As of March 31, 2024, working capital was $20,616,492 (December 31, 2023 - $20,172,833) and the Company has no substantial commitments that require significant outlays of cash over the coming fiscal year.

Other than as disclosed above, the Company does not anticipate any capital requirements for the twelve months ending December 31, 2024.

Other than as disclosed above, the Company does not know of any trends, demands, commitments, events or uncertainties that will result in, or that are reasonable likely to result in, its liquidity increasing or decreasing in any material way.

See Note 2 to the condensed interim consolidated financial statements included as part of this report for a description of the Company’s significant accounting policies.

24

Item 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Under the direction and with the participation of our management, including our Principal Executive and Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2024. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and that such information is accumulated and communicated to our management, including our principal executive and financial officer, as appropriate, to allow timely decisions regarding required disclosure. Our disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching desired disclosure control objectives. Based on the evaluation, our Principal Executive and Financial Officer concluded that these disclosure controls and procedures are effective as of March 31, 2024

Changes in Internal Control over Financial Reporting

Our management, with the participation of our Principal Executive and Financial Officer, evaluated whether any change in our internal control over financial reporting occurred during the three months ended March 31, 2024. Based on that evaluation, it was concluded that there has been no change in our internal control over financial reporting during the three months ended March 31, 2024 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II

Item 5. Other Information

None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period ending March 31, 2024

Item 6. Exhibits.

Number Description
3.1 Articles of Continuance (Articles of Incorporation) (1)
3.2 Bylaws (2)
31.1 Certification of Principal Executive Officer Pursuant to §302 of the Sarbanes-Oxley Act of 2002.*
31.2 Certification of Principal Financial Officer Pursuant to §302 of the Sarbanes-Oxley Act of 2002.*
32.1 Certification of Principal Executive and Financial Officer Pursuant to 18 U.S.C. §1350 and §906 of the Sarbanes-Oxley Act of 2002.*
101.INS Inline XBRL Instance Document
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed with this report.

(1) Incorporated by reference the same exhibit filed with the Company’s March 31, 2022 10-Q report.
(2) Incorporated by reference to Exhibit 3(ii) filed the Company’s 8-K report dated April 10, 2022.

25

SIGNATURES

In accordance with the requirements of Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

May 15, 2024

Flexible Solutions International, Inc.
By: /s/ Daniel B. O’Brien
Name: Daniel B. O’Brien
Title: President and Principal Executive Officer
By: /s/ Daniel B. O’Brien
Name: Daniel B. O’Brien
Title: Principal Financial and Accounting Officer

26

TABLE OF CONTENTS